R. Paul Wadwa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
R. Paul Wadwa has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- David M. Maahs
Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado, USA
5 shared publications - Franziska K. Bishop
Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO, United States
5 shared publications - Georgeanna J. Klingensmith
Barbara Davis Center for Childhood Diabetes, University of Colorado and Children's Hospital Colorado, Aurora, Colorado
2 shared publications - Janet K. Snell-Bergeon
Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
2 shared publications - Kim McFann
Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, 1775 Aurora Ct, Aurora, CO 80045, USA
2 shared publications - Marian Rewers
Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, 1775 Aurora Ct, Aurora, CO, 80045, USA.
2 shared publications
Latest Publications
- 1 September 2019
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 33 (9) , 648-650
Serum uromodulin is associated with urinary albumin excretion in adolescents with type 1 diabetes
- 1 September 2019
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 33 (9) , 648-650
Serum uromodulin is associated with urinary albumin excretion in adolescents with type 1 diabetes
- Open Access
- 26 September 2018
- Published by Springer Nature in Current Diabetes Reports
- Vol. 18 (11) , 1-10
Biopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a Call to the Technology Field
Purpose of Review Summarize biopsychosocial factors associated with using continuous glucose monitors (CGMs), insulin pumps, and artificial pancreas (AP) systems and provide a “call to the field” about their importance to technology uptake and maintained use. Recent Findings Insulin pumps and CGMs are becoming standard of care for individuals with type 1 diabetes (T1D). AP systems combining a CGM, insulin pump, and automated dosing algorithm are available for commercial use. Despite improved glycemic control with AP system use, numerous barriers exist which may limit their benefit. Studies on components of AP systems (pumps, CGMs) are limited and demonstrate mixed results of their impact on fear of hypoglycemia, adherence, quality of life, depression and anxiety, and diabetes distress. Studies examining biopsychological factors associated specifically with sustained use of AP systems are also sparse. Summary Biological, psychological and social impacts of AP systems have been understudied and the information they provide has not been capitalized upon.
- 26 September 2018
- Published by Springer Nature in Current Diabetes Reports
- Vol. 18 (11) , 1-10
Open AccessBiopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a Call to the Technology Field
Purpose of Review Summarize biopsychosocial factors associated with using continuous glucose monitors (CGMs), insulin pumps, and artificial pancreas (AP) systems and provide a “call to the field” about their importance to technology uptake and maintained use. Recent Findings Insulin pumps and CGMs are becoming standard of care for individuals with type 1 diabetes (T1D). AP systems combining a CGM, insulin pump, and automated dosing algorithm are available for commercial use. Despite improved glycemic control with AP system use, numerous barriers exist which may limit their benefit. Studies on components of AP systems (pumps, CGMs) are limited and demonstrate mixed results of their impact on fear of hypoglycemia, adherence, quality of life, depression and anxiety, and diabetes distress. Studies examining biopsychological factors associated specifically with sustained use of AP systems are also sparse. Summary Biological, psychological and social impacts of AP systems have been understudied and the information they provide has not been capitalized upon.
- Open Access
- 19 April 2016
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2016 (1) , 1-8
Influences of gender on cardiovascular disease risk factors in adolescents with and without type 1 diabetes
Women with type 1 diabetes (T1D) have a four-fold increased risk for cardiovascular disease (CVD) compared to non-diabetic (non-DM) women, as opposed to double the risk in T1D men compared to non-DM men. It is unclear how early in life CVD risk differences begin in T1D females. Therefore, our objective was to compare CVD risk factors in adolescents with and without T1D to determine the effects of gender on CVD risk factors. The study included 300 subjects with T1D (age 15.4±2.1 years, 50 % male, 80 % non-Hispanic White (NHW), glycated hemoglobin (A1c) 8.9±1.6 %, diabetes duration 8.8±3.0 years, BMI Z-score 0.62±0.77) and 100non-DM controls (age 15.4±2.1 years, 47 % male, 69 % NHW, BMI Z-score 0.29±1.04). CVD risk factors were compared by diabetes status and gender. Multivariate linear regression analyses were used to determine if relationships between diabetes status and CVD risk factors differed by gender independent of differences in A1c and BMI. Differences in CVD risk factors between T1D subjects and non-DM controls were more pronounced in girls. Compared to boys with T1D and non-DM girls, T1D girls had higher A1c (9.0 % vs. 8.6 % and 5.1 %, respectively), BMI Z-score (0.70 vs. 0.47 and 0.27), LDL-c (95 vs. 82 and 81 mg/dL), total cholesterol (171 vs. 153 and 150 mg/dL), DBP (68 vs. 67 and 63 mmHg), and hs-CRP (1.15 vs. 0.57 and 0.54 mg/dL) after adjusting for Tanner stage, smoking status, and race/ethnicity (p <0.05 for all). In T1D girls, differences in lipids, DBP, and hs-CRP persisted even after adjusting for centered A1c and BMI Z-score. Testing interactions between gender and T1D with CVD risk factors indicated that differences were greater between girls with T1D and non-DM compared to differences between boys with T1D and non-DM. Overall, observed increases in CVD risk factors in T1D girls remained after further adjustment for centered A1c or BMI Z-score. Interventions targeting CVD risk factors in addition to lowering HbA1c and maintaining healthy BMI are needed for youth with T1D. The increased CVD risk factors seen in adolescent girls with T1D in particular argues for earlier intervention to prevent later increased risk of CVD in women with T1D.
- 19 April 2016
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2016 (1) , 1-8
Open AccessInfluences of gender on cardiovascular disease risk factors in adolescents with and without type 1 diabetes
Women with type 1 diabetes (T1D) have a four-fold increased risk for cardiovascular disease (CVD) compared to non-diabetic (non-DM) women, as opposed to double the risk in T1D men compared to non-DM men. It is unclear how early in life CVD risk differences begin in T1D females. Therefore, our objective was to compare CVD risk factors in adolescents with and without T1D to determine the effects of gender on CVD risk factors. The study included 300 subjects with T1D (age 15.4±2.1 years, 50 % male, 80 % non-Hispanic White (NHW), glycated hemoglobin (A1c) 8.9±1.6 %, diabetes duration 8.8±3.0 years, BMI Z-score 0.62±0.77) and 100non-DM controls (age 15.4±2.1 years, 47 % male, 69 % NHW, BMI Z-score 0.29±1.04). CVD risk factors were compared by diabetes status and gender. Multivariate linear regression analyses were used to determine if relationships between diabetes status and CVD risk factors differed by gender independent of differences in A1c and BMI. Differences in CVD risk factors between T1D subjects and non-DM controls were more pronounced in girls. Compared to boys with T1D and non-DM girls, T1D girls had higher A1c (9.0 % vs. 8.6 % and 5.1 %, respectively), BMI Z-score (0.70 vs. 0.47 and 0.27), LDL-c (95 vs. 82 and 81 mg/dL), total cholesterol (171 vs. 153 and 150 mg/dL), DBP (68 vs. 67 and 63 mmHg), and hs-CRP (1.15 vs. 0.57 and 0.54 mg/dL) after adjusting for Tanner stage, smoking status, and race/ethnicity (p <0.05 for all). In T1D girls, differences in lipids, DBP, and hs-CRP persisted even after adjusting for centered A1c and BMI Z-score. Testing interactions between gender and T1D with CVD risk factors indicated that differences were greater between girls with T1D and non-DM compared to differences between boys with T1D and non-DM. Overall, observed increases in CVD risk factors in T1D girls remained after further adjustment for centered A1c or BMI Z-score. Interventions targeting CVD risk factors in addition to lowering HbA1c and maintaining healthy BMI are needed for youth with T1D. The increased CVD risk factors seen in adolescent girls with T1D in particular argues for earlier intervention to prevent later increased risk of CVD in women with T1D.
- 1 January 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (1) , 7-14
Use of Telemedicine to Improve Adherence to American Diabetes Association Standards in Pediatric Type 1 Diabetes
Background: The American Diabetes Association (ADA) recommends that children with type 1 diabetes (T1D) see a multidisciplinary team and have hemoglobin A1c (A1C) levels measured every 3 months. Patients in rural areas may not follow guidelines because of limited specialty care access. We hypothesized that videoconferencing would result in equivalent A1C compared with in-person visits and increased compliance with ADA recommendations. Materials and Methods: The Barbara Davis Center (BDC) (Aurora, CO) telemedicine program provides diabetes care to pediatric patients in Casper and Cheyenne, WY, via remote consultation with annual in-person visits. Over 27 months, 70 patients were consented, and 54 patients completed 1 year in the study. Results: Patients were 70% male, with a mean age of 12.1 ± 4.1 years and T1D duration of 5.4 ± 4.1 years. There was no significant change between baseline and 1-year A1C levels for patients with data at both time points. Patients saw diabetes specialists an average of 2.0 ± 1.3 times per year in the year prior to starting telemedicine and 2.9 ± 1.3 times ( P < 0.0001) in the year after starting telemedicine. Patients and families missed significantly less school and work time to attend appointments. Conclusions: Our study suggests telemedicine is equivalent to in-person visits to maintain A1C, whereas families increase the number of visits in line with ADA recommendations. Patients and families miss less school and work. Decreased financial burden and increased access may improve overall diabetes care and compliance for rural patients. Further study is needed to detect long-term differences in complications screenings and the financial impact of telemedicine on pediatric diabetes care.
- 1 January 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (1) , 7-14
Use of Telemedicine to Improve Adherence to American Diabetes Association Standards in Pediatric Type 1 Diabetes
Background: The American Diabetes Association (ADA) recommends that children with type 1 diabetes (T1D) see a multidisciplinary team and have hemoglobin A1c (A1C) levels measured every 3 months. Patients in rural areas may not follow guidelines because of limited specialty care access. We hypothesized that videoconferencing would result in equivalent A1C compared with in-person visits and increased compliance with ADA recommendations. Materials and Methods: The Barbara Davis Center (BDC) (Aurora, CO) telemedicine program provides diabetes care to pediatric patients in Casper and Cheyenne, WY, via remote consultation with annual in-person visits. Over 27 months, 70 patients were consented, and 54 patients completed 1 year in the study. Results: Patients were 70% male, with a mean age of 12.1 ± 4.1 years and T1D duration of 5.4 ± 4.1 years. There was no significant change between baseline and 1-year A1C levels for patients with data at both time points. Patients saw diabetes specialists an average of 2.0 ± 1.3 times per year in the year prior to starting telemedicine and 2.9 ± 1.3 times ( P < 0.0001) in the year after starting telemedicine. Patients and families missed significantly less school and work time to attend appointments. Conclusions: Our study suggests telemedicine is equivalent to in-person visits to maintain A1C, whereas families increase the number of visits in line with ADA recommendations. Patients and families miss less school and work. Decreased financial burden and increased access may improve overall diabetes care and compliance for rural patients. Further study is needed to detect long-term differences in complications screenings and the financial impact of telemedicine on pediatric diabetes care.
- Open Access
- 15 August 2014
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2014 (1) , 17
Changes in diet and physical activity in adolescents with and without type 1 diabetes over time
Diet and physical activity (PA) are fundamental aspects of care in type 1 diabetes, but scant longitudinal data exist on these behaviors in adolescents with type 1 diabetes, especially compared to non-diabetic controls.
- 15 August 2014
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2014 (1) , 17
Open AccessChanges in diet and physical activity in adolescents with and without type 1 diabetes over time
Diet and physical activity (PA) are fundamental aspects of care in type 1 diabetes, but scant longitudinal data exist on these behaviors in adolescents with type 1 diabetes, especially compared to non-diabetic controls.
- Open Access
- 22 May 2014
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 13 (1) , 59
The effect of insurance status and parental education on glycemic control and cardiovascular disease risk profile in youth with Type 1 Diabetes
Adult studies have shown a correlation between low socioeconomic status and Type 1 Diabetes complications, but studies have not been done in children to examine the effect of socioeconomic status on risk for future complications. This study investigates the relationship between insurance status and parental education and both glycemic control and cardiovascular disease (CVD) risk factors in youth with type 1 diabetes.
- 22 May 2014
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 13 (1) , 59
Open AccessThe effect of insurance status and parental education on glycemic control and cardiovascular disease risk profile in youth with Type 1 Diabetes
Adult studies have shown a correlation between low socioeconomic status and Type 1 Diabetes complications, but studies have not been done in children to examine the effect of socioeconomic status on risk for future complications. This study investigates the relationship between insurance status and parental education and both glycemic control and cardiovascular disease (CVD) risk factors in youth with type 1 diabetes.
- 6 May 2014
- Published by Springer Nature in Current Diabetes Reports
- Vol. 14 (7) , 1-8
Risks and Benefits of Statin Use in Young People with Type 1 Diabetes
Cardiovascular disease (CVD) is the primary cause of mortality in patients with type 1 diabetes (T1D). Despite advances in the management of microvascular complications of T1D, there is a lack of similar progress in reduction of macrovascular complications. Dyslipidemia is one of the major contributory factors for macrovascular complications in T1D, but the literature suggests significant under-treatment of this risk factor in children and adolescents with diabetes. Statins have shown to be both effective and safe in young people with familial hypercholesterolemia and adults with diabetes mellitus, but the role for statins in children and adolescent with T1D remains unclear and controversial. In this review, we will summarize the risks and benefits of statin use in young people with T1D.
- 6 May 2014
- Published by Springer Nature in Current Diabetes Reports
- Vol. 14 (7) , 1-8
Risks and Benefits of Statin Use in Young People with Type 1 Diabetes
Cardiovascular disease (CVD) is the primary cause of mortality in patients with type 1 diabetes (T1D). Despite advances in the management of microvascular complications of T1D, there is a lack of similar progress in reduction of macrovascular complications. Dyslipidemia is one of the major contributory factors for macrovascular complications in T1D, but the literature suggests significant under-treatment of this risk factor in children and adolescents with diabetes. Statins have shown to be both effective and safe in young people with familial hypercholesterolemia and adults with diabetes mellitus, but the role for statins in children and adolescent with T1D remains unclear and controversial. In this review, we will summarize the risks and benefits of statin use in young people with T1D.
- Open Access
- 24 October 2013
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2013 (1) , 17
Lower A1c among adolescents with lower perceived A1c goal: a cross-sectional survey
- 24 October 2013
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2013 (1) , 17
Open AccessLower A1c among adolescents with lower perceived A1c goal: a cross-sectional survey
- Open Access
- 30 July 2012
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2012 (1) , 24
Lessons learned from a lipid lowering trial in adolescents with type 1 diabetes
Herein, we describe recruitment efforts for a trial of lipid-lowering medications in adolescents with type 1 diabetes, age 12–21 years. Based on our experience, future studies will require multiple centers to enroll a sufficient number of participants for adequate data to direct dyslipidemia medication treatment guidelines for adolescents with type 1 diabetes.
- 30 July 2012
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2012 (1) , 24
Open AccessLessons learned from a lipid lowering trial in adolescents with type 1 diabetes
Herein, we describe recruitment efforts for a trial of lipid-lowering medications in adolescents with type 1 diabetes, age 12–21 years. Based on our experience, future studies will require multiple centers to enroll a sufficient number of participants for adequate data to direct dyslipidemia medication treatment guidelines for adolescents with type 1 diabetes.
- 1 December 2011
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 13 (12) , 1269-1270
Vascular Measures to Detect Earlier Macrovascular Disease
- 1 December 2011
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 13 (12) , 1269-1270
Vascular Measures to Detect Earlier Macrovascular Disease